SCHEMBL20252602

SCHEMBL20252602

COc1ccc(CN(c2cnccn2)S(=O)(=O)c2cc(Cl)c(F)cc2F)c(C)c1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS3 P29474 2/20 0.34
NOS1 P29475 2/20 0.34
NOS2 P35228 2/20 0.34
NFE2L2 Q16236 1/20 0.33
NAMPT P43490 2/20 0.33
PSEN1 P49768 2/20 0.33
PSEN2 P49810 2/20 0.33
APH1B Q8WW43 2/20 0.33
NCSTN Q92542 2/20 0.33
APH1A Q96BI3 2/20 0.33
PSENEN Q9NZ42 2/20 0.33
RAB9A P51151 1/20 0.33
SCN1A P35498 1/20 0.33
SCN5A Q14524 1/20 0.33
SCN8A Q9UQD0 1/20 0.33
ACLY P53396 1/20 0.32
GAA P10253 2/20 0.32
PKM P14618 1/20 0.32
SMN1; SMN2 Q16637 1/20 0.32
P2RX7 Q99572 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20238539 0.93 GAA (0.37) NFE2L2NAMPTRAB9AGAASMN1; SMN2
SCHEMBL20252647 0.88 ALDH1A1 (0.33) NFE2L2PSEN1PSEN2APH1BNCSTN
SCHEMBL20252608 0.85 EGFR (0.33) NOS1NOS2PSEN1PSEN2APH1B
SCHEMBL19627680 0.84 SCN8A (0.40) SCN1ASCN5ASCN8AACLY
SCHEMBL16185274 0.84 MEN1 (0.33) NOS3NOS1NOS2NFE2L2PSEN1
SCHEMBL20252607 0.84 SCN1A (0.57) SCN1ASCN5ASCN8A
SCHEMBL18352355 0.83 CNR1 (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL18352647 0.83 CNR1 (0.44) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL18352659 0.83 CNR1 (0.37) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL18352237 0.83 SCN1A (0.35) PSEN1PSEN2APH1BNCSTNAPH1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180162868-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162868-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B NOS3 3210/4885NOS1 3537/4885NOS2 3744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.